Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.89 |
| ▸ | PARP1 | P09874 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | PHGDH | O43175 | 2/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | RRM1 | P23921 | 1/20 | 0.73 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.73 |
| ▸ | KDM4A | O75164 | 1/20 | 0.72 |
| ▸ | KDM4B | O94953 | 1/20 | 0.72 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562127 | 0.94 | SCD (1.00) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL23674562 | 0.94 | SCD (0.84) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL1883572 | 0.93 | PARP1 (0.92) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL13206963 | 0.93 | SCD (0.82) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL17107144 | 0.91 | PARP1 (1.00) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL27986824 | 0.91 | SCD (0.76) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL17107148 | 0.90 | SCD (0.78) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL2753872 | 0.90 | LMNA (0.77) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL17107123 | 0.90 | LMNA (0.76) | SCDPARP1LMNAPHGDHADORA3 | |
| SCHEMBL17107249 | 0.90 | SCD (0.78) | SCDPARP1LMNAPHGDHADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | claimed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | claimed |
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | XAVIER UNIVERSITY OF LOUISIANA | 2015-10-01 | — | — | US | claimed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | claimed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | claimed |
| EP-2459554-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | claimed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | claimed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | claimed |
| WO-2011013141-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-03 | — | — | WO | claimed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| CN-114222574-A | Inhibition of USP36 | 瓦洛健康股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| US-9718784-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717709-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973169-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7777041-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
| US-7504511-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | MKI67, MIF, NUDC | SCD 4368/4885PARP1 2439/4885LMNA 1937/4885 |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | HSF1, HSP90AB1, HSPBP1 | SCD 2809/4885PARP1 2222/4885LMNA 4374/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | SCD 2582/4885PARP1 181/4885LMNA 621/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | SCD 1560/4885PARP1 2787/4885LMNA 3403/4885 |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | SCD 1560/4885PARP1 2787/4885LMNA 3403/4885 |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | PAH, ABAT, AADAT | SCD 4070/4885PARP1 3520/4885LMNA 4028/4885 |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | SCD 149/4885PARP1 4477/4885LMNA 224/4885 |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | SCD 1560/4885PARP1 2787/4885LMNA 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.